The Cytotoxicity of Gefitinib on Patient-Derived Induced Pluripotent Stem Cells Reflects Gefitinib-Induced Liver Injury in the Clinical Setting

Patient‑derived iPSCs were generated by reprogramming peripheral blood mononuclear cells obtained from two groups of gefitinib‑treated patients with severe hepatotoxicity or mild hepatotoxicity.